Article Sidebar

Download
Requires Subscription PDF
Statistic
Read Counter : 193 Download : 8

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Main Article Content

Abstract

BACKGROUND


Metastatic gastric carcinoma patients usually present late and are not suitable for any form of chemotherapy. Inflammatory markers like neutrophil-lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) may be used to predict survival and for selecting patients for palliative gastrectomy. We wanted to determine the prognostic value of NLR and PLR on survival in metastatic gastric carcinoma patients undergoing palliative gastrectomy.


METHODS


We retrospectively analyzed data of 156 metastatic gastric carcinoma patients admitted from August 2011 to January 2020 in a tertiary centre in India. Among these, 43 who underwent palliative gastrectomy and 53 who underwent only best supportive care were included in the study.


RESULTS


The optimum cut-off value (NLR - 3.5, PLR - 183.5) was based on the ROC curve. The overall survival was significantly better in the palliative gastrectomy group (4.953 months vs. 2.434 months) (P=0.013). The mean overall survival was also better in the low-PLR group (6.81 vs. 4.81 months) (P= 0.043) and low -NLR group (6.80 vs. 4.91 months) although the latter was not statistically significant (P=0.053).


CONCLUSIONS


Patients undergoing palliative gastrectomy for metastatic gastric cancer have significantly better survival, especially those with low PLR and NLR ratios, although the latter was not statistically significant.

Keywords

Palliative, Gastrectomy, Survival, Supportive Care

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Pradeep Kumar S., Senthil G., Kalayarasan R., & Biju Pottakkat. (2022). Prognostic Value of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio on Survival of Patients Undergoing Palliative Gastrectomy for Metastatic Gastric Carcinoma - A Single Centre Experience. Journal of Evolution of Medical and Dental Sciences, 11(6), 612–617. https://doi.org/10.14260/jemds.v11i6.121
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Zhang Y, Lu JJ, Du YP, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. Medicine (Baltimore) 2018;97(12):e0144.
  2. Yokota T, Takahashi N, Teshima S, et al. Early gastric cancer in the young: clinicopathologic study. Aus N J Surg 1999;69(6):321-4.
  3. Yokota T, Kunii Y, Teshima S, et al. Signet ring cell carcinoma of the stomach: a clinicopathological comparison with the other histological types. Tohoku J Exp Med 1998;186(2):121-30.
  4. Yokota T, Saito T, Teshima S, et al. Lymph node metastasis in early gastric cancer: how can surgeons perform limited surgery? Int Surg 1998;83(4):287-90.
  5. Yokota T, Kunii Y, Teshima S, et al. Gastric cancer with invasion limited to the proper muscle. Int Surg 1999;84(1):7-12.
  6. Yokota T, Teshima S, Saito T, et al. Borrmann type IV gastric cancer: clinicopathological analysis. Can J Surg 1999;42(5):371-6.
  7. Yokota T, Kunii Y, Teshima S, et al. Significant prognostic factors in patients with node-negative gastric cancer. Int Surg 1999;84(4):331-6.
  8. Yokota T, Kunii Y, Teshima S, et al. Significant prognostic factors in patients with early gastric cancer. Int Surg 2000;85(4):286-90.
  9. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000;88(4):921-32.
  10. Moehler M, Galle PR, Gockel I, et al. Multimodal treatment of gastric cancer. Best Pract Res Clin Gastroenterol 2007;21(6):965-81.
  11. Meyer L, Meyer F, Gastinger I, et al. Qualitätssicherungsstudie zum Magenkarzinom in Deutschland. Der Onkologe 2008;14:396-402.
  12. Bozzetti F, Bonfanti G, Audisio RA, et al. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynecol Obstet 1987;164(2):151-4.
  13. Miner TJ, Jaques DP, Karpeh MS, et al. Defining palliative surgery in patients receiving noncurative resections for gastric cancer. J Am Coll Surg 2004;198(6):1013-21.
  14. Lawrence W, McNeer G. The effectiveness of surgery for palliation of incurable gastric cancer. Cancer 1958;11(1):28-32.
  15. Kunisaki C, Makino H, Takagawa R, et al. Impact of palliative gastrectomy in patients with incurable advanced gastric cancer. Anticancer Res 2008;28(2B):1309-15.
  16. Alifano M, Mansuet-Lupo A, Lococo F, et al. Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS One 2014;9(9):e106914.
  17. Semenza GL, Ruvolo PP. Introduction to tumor microenvironment regulation of cancer cell survival, metastasis, inflammation, and immune surveillance. Biochim Biophys Acta 2016;1863(3):379-81.
  18. Rivas-Fuentes S, Salgado-Aguayo A, Belloso SP, et al. Role of chemokines in non-small cell lung cancer: angiogenesis. and inflammation. J Cancer 2015;6(10):938-52.
  19. Chen Y, Zhang L, Liu WX, et al. Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in Chinese women with epithelial ovarian cancer. Asian Pac J Cancer Prev 2015;16(3):933-9.
  20. Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin. J Immunol Res 2015;2015:983698.
  21. Mezouar S, Frere C, Darbousset R, et al. Role of platelets in cancer and cancer-associated thrombosis: experimental and clinical evidences. Thromb Res 2016;139:65-76.
  22. Li N. Platelets in cancer metastasis: to help the “villain” to do evil. Int J Cancer 2016;138(9):2078-87.
  23. Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc 2010;8(4):437-47.
  24. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017;8(8):CD004064.
  25. Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer 2009;12(3):132-41.
  26. Meza-Junco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009;9(12):1543-51.
  27. Huang KH, Wu CW, Fang WL, et al. Palliative resection in noncurative gastric cancer patients. World J Surg 2010;34:1015-21.
  28. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21(2):137-48.
  29. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;67(2):93-9.